

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10565308
Filing Date	2006-03-27
First Named Inventor	Thomas Helleday
Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	J660-065 US

U.S.PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/BK/	1	6495541	B1	2002-12-17	Webber, et al.	
/BK/	2	6548494	B1	2003-04-15	Webber, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/BK/	1	20060074073	A1	2006-04-06	Steinfeldt, et al.	
	2	20050227919	A1	2005-10-13	Ashworth, et al.	
↓	3	20050059663	A1	2005-03-17	Martin, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add**FOREIGN PATENT DOCUMENTS****Remove**

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10565308
Filing Date	2006-03-27
First Named Inventor	Thomas Helleday
Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	J660-065 US

/BK/	1	2005012524	WO	A1	2005-02-10	The University of Sheffield, et al.	<input type="checkbox"/>
	2	2004087713	WO	A1	2004-10-14	Pfizer, Inc., et al.	<input type="checkbox"/>
	3	0116136	WO	A2	2001-03-08	Agouron Pharmaceuticals, Inc., et al.	<input type="checkbox"/>
↓	4	0042040	WO	A1	2000-07-20	Agouron Pharmaceuticals, Inc., et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
/BK/	1	BRYANT, et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, April 14, 2005, 913-917, Vol. 434.	<input type="checkbox"/>
	2	CANAN KOCH, et al., Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal Structure, J. Med. Chem., 2002, 4961-4974, Vol. 45, No. 23.	<input type="checkbox"/>
	3	EASTON, et al., Cancer Risks in BRCA2 Mutation Carriers, J. Natl. Cancer Inst., 1999, 1310-1316, Vol. 91, No. 15.	<input type="checkbox"/>
	4	FARMER, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, April 14, 2005, 917-921, Vol. 434.	<input type="checkbox"/>
↓	5	FRIEDENSON, et al., BRCA1 and BRCA2 Pathways and the Risk of Cancers Other Than Breast or Ovarian, Medscape General Medicine, 2005, 7(2):60.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10565308
Filing Date	2006-03-27
First Named Inventor	Thomas Helleday
Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	J660-065 US

/BK/	6	LAKHANI, et al., The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2, Journal of Clinical Oncology, May 1, 2002, 2310-2318, Vol. 20, No. 9.	<input type="checkbox"/>
	7	QUINN, et al., BRCA1 Functions as a Different Modulator of Chemotherapy-induced Apoptosis, Cancer Research, October 1, 2003, 6221-6228, Vol. 63.	<input type="checkbox"/>
	8	TARON, et al., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer, Human Molecular Genetics, 2004, 2443-2449, Vol. 13, No. 20.	<input type="checkbox"/>
	9	TUTT, et al., The relationship between the roles of BRCA genes in DNA repair and cancer predisposition, Trends in Molecular Medicine, December 2002, 571-576, Vol. 8, No. 12.	<input type="checkbox"/>
	10	VENKITARAMAN, A. R., Cancer Susceptibility and the Functions of BRCA1 and BRCA2, Cell, January 25, 2002, 171-182, Vol. 108.	<input type="checkbox"/>
	11	PCT International Search Report for PCT/GB2004/003183 (WO 2005/012305).	<input type="checkbox"/>
↓	12	PCT Written Opinion of the International Searching Authority for PCT/GB2004/003183 (WO 2005/012305).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Bruck Kifle/ (07/19/2007)	Date Considered	07/19/2007
--------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.